Please login to the form below

Not currently logged in
Email:
Password:

Roche increases offer price for Genentech

Roche has increased its offer price for all outstanding publicly held shares of Genentech to $93 per share

Roche has increased its offer price for all outstanding publicly held shares of Genentech to $93 per share and extended the offer to 12:00 midnight, New York City time, on Friday, March 20, 2009. All other terms and conditions of the tender offer remain unchanged.

Franz B Humer, chairman of the Roche Group, said: "Based on conversations with Genentech shareholders, we believe there is a strong sentiment to bring this process to a conclusion. As a result, we are increasing our price to $93 per share."

The Offer to Purchase, Letter of Transmittal and other offering documents have been filed with the US Securities and Exchange Commission. As of the close of business on March 5, 2009, approximately 500,000 shares have been tendered pursuant to the offer.

9th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics